An observational study in Papillary Thyroid Cancer, Pediatric Cancer and Differentiated Thyroid Cancer, sponsored by Children's Hospital of Philadelphia. Active, not recruiting at 8 sites in 2 countries. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Children's Hospital of Philadelphia · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Thyroid Cancer, Papillary with a site in United States — 8 open to participants now, 18 under way, 1 of them phase 3. Thyroid Cancer, Papillary · United States.
Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, this one is one of 6 that started in 2021, is one of 9 observational ones, reaches primary completion later than 8 of the 16 other live ones, and was the 64th registered.
187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.
Browse Thyroid Cancer, Papillary studies →8 of the 76 studies in Thyroid Cancer, Papillary with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Jochen Lorch · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 6 mo–98 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 0 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 42 · Phase 3 2
First in 1977; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 200 across 67 observational studies indexed under Thyroid Cancer, Papillary.
Median enrollment 25 across the 62 interventional studies, 50 across the 9 observational. Of the 55 that completed or were terminated, 29 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 76 have an industry lead sponsor. The 10 most frequent:
Children's Hospital of Philadelphia is the lead sponsor of 490 studies on the registry; 90 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 22 (79%) have results posted.
Children's Hospital of Philadelphia has 1 study filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
6 of the studies in Thyroid Cancer, Papillary with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06440850City of Hope Medical CenterVemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | 2026-11-22 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
| NCT07545837Mayo ClinicHealth and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors | 2027-06-30 |
| NCT05024929Children's Hospital of PhiladelphiaTargeted Therapy to Increase RAI Uptake in Metastatic DTC | 2027-07 |
| NCT04544111Memorial Sloan Kettering Cancer CenterPDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | 2027-09-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 76 studies in Thyroid Cancer, Papillary with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC have become available. While Investigators know that these drugs shrink DTC tumors in many cases, the impact on radioactive iodine (RAI) avidity has not been systematically studied.
This is an observational cohort study that will enroll patients with DTC metastatic to the lungs who will receive oncogene-specific targeted therapy as part of routine clinical care or a separate therapeutic clinical trial. After approximately 4 weeks of therapy, patients will have a whole body scan to determine the change in RAI-avidity of their tumor from baseline. Subsequent therapy will be at the discretion of the treating physician or according to the therapeutic trial on which the patient is enrolled.
This study will enroll children and adolescents with differentiated thyroid cancer with pulmonary metastases who are planned to receive oncogene-specific targeted therapy.
Inclusion Criteria (Prospective Cohort):
Anatomically evaluable disease on chest Computed tomography (CT) meeting oneo f the following criteria (obtained within 180 days of enrollment):
Patients for whom systemic therapy with an oncogene-specific kinase inhibitor is planned from commercial supply or as part of a separate therapeutic clinical trial (that does not include data sharing with this protocol)/compassionate access protocol/single patient new drug (IND). Such agents include, but are not limited to:
Inclusion Criteria (Data Sharing Cohort):
1. Patients enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing as part of the consent process for that trial.
Exclusion Criteria (All Cohorts):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with differentiated thyroid cancer for whom oncogene-specific targeted therapy is planned from commercial supply or as part of a separate therapeutic trial
Procedure: Whole body scan
Patients with differentiated thyroid cancer enrolled on other oncogene-specific targeted therapy trials who undergo whole body thyroid scan approximately 28 days after beginning targeted therapy and agree to data sharing
Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND). During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.
Proportion of patients with increased tumor RAI-avidity after receiving oncogene-specific, targeted therapy
The primary outcome measure is to determine the proportion of patients with differentiated thyroid cancer metastatic to the lungs for whom oncogene-specific, targeted therapy increases tumor RAI-avidity.
Time frame: up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Jul 2027, 72 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Feb 2031 → Jul 2027 and completion Feb 2033 → Jul 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Children's Hospital of Philadelphia →